TECH — BIO-TECHNE Corp

Nasdaq · Health Care · Biotechnology · CIK 842023 ·
Last close
$54.00
Market Cap
$8.45B
52W High
$62.35
52W Low
$43.12
ADV30
3,336,460
Next earnings
2026-08-05
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 295,877,000 191,277,000 54,461,000 38,009,000 2,522,699,000 172,879,000 511,710,000
Sep 2025 286,555,000 188,112,000 47,658,000 38,185,000 2,526,148,000 144,962,000 560,334,000
Jun 2025 316,964,000 198,812,000 116,689,000 -17,678,000 2,557,868,000 162,186,000 639,060,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$249,317,000
Investing CF
$-13,783,000
Financing CF
$-251,687,000
CapEx
$-26,297,000
Dividends Paid
$-49,881,000
Buybacks
$-200,127,000
EPS Diluted TTM
$0.69
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$1,106,819,000
Inventory
$205,447,000
Receivables
$184,614,000
ST Investments
EBIT TTM
$83,199,000
Pretax Income TTM
$75,916,000
Interest Exp TTM
$7,283,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,210,811,008
EBITDA
$366,044,992
Free Cash Flow
$299,849,376
Enterprise Value
$8,530,920,448
Total Cash
$214,114,000
Total Debt
$290,321,984
Shares Out
156,568,751
Trailing EPS
$0.70
Book Value
$12.90
ROE
5.3%
ROA
7.5%
Div Yield
0.59%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 1,219,635,000 242,804,000 73,400,000 2,557,868,000 639,060,000 287,556,000
Jun 2024 1,159,060,000 246,401,000 168,105,000 2,703,867,000 635,017,000 298,981,000
Jun 2023 1,136,702,000 290,998,000 285,263,000 2,638,692,000 672,176,000 254,393,000
Jun 2022 1,105,599,000 295,828,000 272,051,000 2,294,805,000 593,794,000 325,272,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.06

Max Pain — expiry 2026-07-17

max pain strike: $55.00 · spot: $56.17 · call oi: 866 · put oi: 1,033
Expected Move to 2026-07-17: ±$6.18 (10.99%) — implied range $49.99$62.34 · ATM straddle on $55.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HALO HALOZYME THERAPEUTICS, INC. $8.24B $69.50
QGEN QIAGEN N.V. $7.64B $37.06
KRYS Krystal Biotech, Inc. $9.37B $317.97
IBRX ImmunityBio, Inc. $7.44B $7.10
RGEN REPLIGEN CORP $7.37B $130.59

News headlines (Yahoo Finance, 1h cache)

Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers
2026-06-15 05:03 · Yahoo
Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now?
2026-06-13 20:43 · Yahoo
SpaceX initiated, Intel upgraded: Wall Street's top analyst calls
2026-06-11 13:38 · Yahoo
1 S&P 500 Stock with Impressive Fundamentals and 2 We Brush Off
2026-06-11 10:33 · Yahoo
New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
2026-06-08 21:19 · Yahoo
3 Reasons TECH is Risky and 1 Stock to Buy Instead
2026-06-08 17:17 · Yahoo
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
2026-06-04 10:30 · Yahoo
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
2026-06-02 12:21 · Yahoo
Are Wall Street Analysts Bullish on Bio-Techne Stock?
2026-05-25 18:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.